Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations

AstraZeneca PLC (AZN) (AZN)

44.66   0.81 (1.85%) 04-09 16:02
Open: 43.91 Pre. Close: 43.85
High: 44.98 Low: 43.5
Volume: 5,595,858 Market Cap: 119545M
AstraZeneca PLC belongs to the healthcare sector. The company develops and markets pharmaceutical products for various therapeutic classes such as gastrointestinal, cardiovascular, respiratory, cancer, immunology, and neuroscience.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 45.035 - 45.202 45.202 - 45.337
Low: 43.053 - 43.262 43.262 - 43.429
Close: 44.333 - 44.659 44.659 - 44.921

Technical analysis

as of: 2020-04-09 4:28:04 PM
Stoxline posted a BUY today, upgraded from lower rating. Upward movement to be expected.
Target: Six months: 55.64     One year: 64.99
Support: Support1: 40.54    Support2: 36.15
Resistance: Resistance1: 47.64    Resistance2: 55.64
Pivot: 42.73
Moving Average: MA(5): 43.98     MA(20): 42.07
MA(100): 47.34     MA(250): 44.31
MACD: MACD(12,26): -0.20     Signal(9): -0.69
Stochastic oscillator: %K(14,3): 82.36     %D(3): 81.87
RSI: RSI(14): 53.28
52-week: High: 51.55  Low: 36.15  Change(%): 13.0
Average Vol(K): 3-Month: 466713  10-Days: 582654

Price, moving averages and Bollinger Bands

Price and moving averages has closed above its Short term moving average. Short term moving average is currently below mid-term; AND below long term moving averages. From the relationship between price and moving averages; we can see that: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
AZN has closed below upper band by 24.6%. Bollinger Bands are 67.5% wider than normal. The large width of the bands suggest high volatility as compared to AZN's normal range. The bands have been in this wide range for 30 bars. This is a sign that the current trend might continue.

Headline News

Clovis Oncology Analyst Turns Bearish Ahead Of PDUFA Date For Rubraca
Despite optimistic expectations concerning label expansion for Clovis Oncology Inc's (NASDAQ: CLVS ) Rubraca to include prostate cancer, an analyst at BofA Securities is turning bearish on the stock. The Clovis Analyst Tazeen Ahmad downgraded Clovis shares from Neutral to Underperform but maintained a $6 price target. The Clovis Thesis The recent run in Clovis shares indicates a high likelihood of the FDA approving Rubraca in second line BRCA+ metastatic castration-resistance prostate cancer, or mCRPC, by the May 15 PDUFA date, Ahmad said in a Thursday note. (See the analyst's track record here .) AstraZeneca plc's (NYSE: AZN ) competing PARP … Full story available on

Collaboration with AstraZeneca, GSK and University of Cambridge to support UK national effort to increase COVID-19 testing - Vox Markets
Novacyt, an international specialist in clinical diagnostics, announces that as part of the UK Government’ s announcement of a new five pillar plan to increase testing for COVID-19, Novacyt is collaborating with AstraZeneca, GSK and the University of Cambridge to take action to support this national effort. A new testing laboratory will be set up by…

Financial Analysis

Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.
Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.
Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.
Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.
Click here to get more fundamental analysis.
Tweet this page Share on Facebook
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  New York Stock Exchange
Sector:  Healthcare
Industry:  Drug Manufacturers - Major
Shares Out. (M) 2620.00
Shares Float (M) 2620.00
% Held by Insiders
% Held by Institutions 18.36
Shares Short (K) 7840
Shares Short P. Month (K) 6820

Stock Financials

EPS 0.510
Book Value (p.s.) 5.000
PEG Ratio 1.58
Profit Margin 5.47
Operating Margin 12.82
Return on Assets (ttm) 3.2
Return on Equity (ttm) 8.6
Qtrly Rev. Growth 3.8
Gross Profit (p.s.) 7.458
Sales Per Share 9.305
EBITDA (p.s.) 2.156
Qtrly Earnings Growth -69.70
Operating Cash Flow (M) 2970.00
Levered Free Cash Flow (M) 6260.00

Stock Valuations

P/E 87.55
P/E Growth Ratio 0.02
P/BV 8.93
P/CF 39.39

Dividends & Splits

Dividend 2.800
Dividend Yield 0.06
Dividend Pay Date 2020-03-29
Ex-Dividend Date 2020-02-26
Forward Dividend 1.400
Last Split Date 2015-07-26
Last Split Ratio 2
7 Binary Options
Your Ad Here
Stock Chart
Stoxline Lite
Stoxline Pro
Option Calculator
(c) 2006-2019 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.